A real-world study on SGLT2 inhibitors and diabetic kidney disease progression

BACKGROUND: Randomized controlled trials have demonstrated the benefits of sodium–glucose cotransporter 2 inhibitors (SGLT2is) in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). However, real-world data on CKD progression and the development of end-stage kidney disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Allen Yan Lun, Low, Serena, Yeoh, Ester, Lim, Eng Kuang, Renaud, Claude Jeffrey, Teoh, Selene Tse Yen, Tan, Grace Feng Ling, Chai, Chung Cheen, Liu, Bo, Subramaniam, Tavintharan, Sum, Chee Fang, Lim, Su Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217649/
https://www.ncbi.nlm.nih.gov/pubmed/35756732
http://dx.doi.org/10.1093/ckj/sfac044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217649/
https://www.ncbi.nlm.nih.gov/pubmed/35756732
http://dx.doi.org/10.1093/ckj/sfac044

Ejemplares similares